PARE0021 TARGETED INITIATIVE TO FACILITATE THE IMPLEMENTATION OF EXISTING EFFECTIVE GOUT TREATMENT IN SWEDEN. (2nd June 2020)

• Record Type: Journal Article
• Authors: Alemo Munters, L.; Loell, I.; Jansson, S.; Jacobsson, L. T. H.; Dehlin, M.
• Is Part Of: Annals of the rheumatic diseases. Volume 79(2020)Supplement 1
• Page Start: 1296
• Page End: 1296
• Publication Date: 2020-06-02
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2020-eular.2807
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Gout is a very painful rheumatic condition origin from excess uric acid in the bloodstream, which results in an accumulation of uric acid crystals in the joints and a severe local inflammatory response. Gout is treated in primary care and the current treatment has satisfactory results on disease management, thus patients can expect a controlled disease without flares. In Sweden however, only 30-40 % (1) of the patients receives adequate urate lowering treatment and prevent the disabling flares. Objectives: As a patient association, the Swedish Rheumatism Association (SRA) has identified an opportunity to use scientific evidence and data to improve awareness in both patients and physicians in order to make the existing treatment available and to shift the gout treatment from flare management to prevention. Methods: With SRA funding we created the Gout network, consisting of researchers, health professionals and patient research partners. Through meetings and operational support developed strategies to educate patients suffering from gout and to alert physicians in the primary care of the most recent research to aid the management of gout. We also fund a specific research project aimed to create an implementation plan to establish a treatment routine for gout in primary care with already existing resources. Results: A high quality patient education material is under development and consists of an information video lecture and a comprehensive online patient school providing information about the diagnosis, preventive treatment, possible life style change along with other resources that will support the gout patient, both for self-care and in relation to healthcare. For the healthcare profession we have together with a clinical research expert and a patient research partner developed a fact sheet with the latest scientific updates on gout. Conclusion: Accessible, high quality diagnosis information about gout is currently missing in Sweden. This collaboration initiative provides high quality facts to raise the general awareness and to educate and empower patients to get the effective therapy that is available today. References: [1] Incidence and prevalence of gout in Western Sweden Dehlin M, Drivelegka P, Sigurdardottir V, Svärd A & Jacobsson LTH. Arthritis Research & Therapy 18, : 164 (2016 ) Disclosure of Interests: Li Alemo Munters: None declared, Ingela Loell: None declared, Suzanna Jansson: None declared, Lennart T.H. Jacobsson Consultant of: AbbVie, Eli Lilly, Janssen, Novartis and Pfizer, Mats Dehlin: None declared